July 6, 2018

Please reload

Recent Posts

FDA Comments on Recently Released Rare Disease Guidance for Industry

September 16, 2015

Jonathan Goldsmith, M.D., F.A.C.P., FDA’s Associate Director, Rare Diseases Program, Center for Drug Evaluation and Research, comments on the recently...

1/2
Please reload

Featured Posts

Dr. Jonathan K. Wilkin, MD, FAAD, joins Patagonia's Advisory Board

November 8, 2014

Patagonia Pharmaceuticals is delighted to announce that Dr. Jonathan K. Wilkin, MD, FAAD, has joined Patagonia's growing Advisory Board.  Dr. Wilkin is the founding Director (retired) of the Division of Dermatology and Dental Products at the US Food and Drug Administration.   Before going to the FDA, he was Director of Dermatology at the Ohio State University and Professor of Pharmacology and Medicine. He has over 130 publications in dermatology and clinical pharmacology.

Dr. Wilkin has served as chairman of the medical advisory board for the National Rosacea Society from 1998 to 2012 as well as having chaired their Expert Committees on the Classification and Staging System for Rosacea. He also has served on the American Academy of Dermatology’s (AAD) Ad Hoc Task Force on the Academy’s Efforts with FDA and on their Environment and Drugs Committee. Dr. Wilkin has been active in the American Society for Clinical Pharmacology and Therapeutics, having chaired the Dermatologic and Allergic Diseases Section and the Constitution and By-laws Committee for several years, as well as serving in other capacities.

Dr. Wilkin is a fellow of the AAD, a member of the American Dermatological Association and board certified by both the American Board of Dermatology and the American Board of Clinical Pharmacology.

 

Patagonia is thrilled to welcome Dr. Wilkin to the team! 

 

Please reload

Patagonia Pharmaceuticals, LLC

50 Tice Blvd, Suite A26

Woodcliff Lake, NJ 07677

For more info: info@patagoniarx.com

© 2019 by Patagonia Pharmaceuticals, LLC